Facebook Instagram Linkedin Twitter Website
Home Blog Page 273

Easton Pharmaceuticals Clinches Distribution Deal with NutraShop

By
IHR Magazine
-
0
Easton Pharmaceuticals Clinches Distribution Deal with NutraShop

Easton Pharmaceuticals Inc. has executed a distribution and intellectual property agreement for its full range of OTC therapeutic and specialty products with NutraShop Global Stores, Inc. currently serving thousands of trusting online customers looking for Quality Life Wellness Products.

Serving an online customer base who are searching for high quality wellness products NutraShop Global Stores have established strong distribution channels that allow the company to sell household specialty brands for less. Many of the products sold online can also be found in major health and grocery stores across the US and Canada, including Wholefoods and Loblaws. NutraShop is currently one of only 2 online retailers to sell the fast-emerging MadeGood Foods brand.

With the push to look better, feel better and live longer healthier lives, NutraShop now features Easton’s new line of wellness products including a cosmetic grade anti-aging serum, pain relief gel and a female health product.

In addition to distributing Easton’s OTC proprietary therapeutic products, Nutrashop has acquired rights and access to Easton’s transdermal delivery system and formulations that are to be utilized in new products being jointly developed, one of which includes a new children’s topical product containing exotic active ingredients to treat certain skin conditions.

NutraShop will compliment their existing road show by highlighting Eastons products over the next two months at the highly anticipated Yoga Show, Health Show and Mom Show throughout the greater Toronto region and upcoming U.S trade shows reaching audiences up to 125,000 looking for natural safe ways to improve health and vitality as well as new possible retail distribution channels.

Carla Pepe, CEO of Easton Pharmaceuticals, stated, “Our new distribution agreement firmly puts our products on the map alongside several already established household brand names. This partnership will set the wheels in motion for the long awaited launch and sales of our OTC and therapeutic products as we showcase our products to customers looking for effective natural solutions online in the US and Canada.”

Salmonella and Listeria Scares Trigger Recalls

By
IHR Magazine
-
0
Salmonella and Listeria Scares Trigger Recalls

It began March 17th with an array of Simply Organic and Frontier seasonings, broths and mixes containing garlic powder. The product was recalled from a number of retailers including Loblaws and Sobey’s. Salmonella usually shows up with classic food poisoning symptoms like diarrhea and abdominal cramps and can be fatal – but no cases of illness have been reported to date.

Samonella concerns continued this week with Aurora Products Inc. recalling their trail mix because of the possibility of contaminated walnuts. The major retailers involved include Giant Food Stores and Stop and Shop stores in the US, as well as Aurora Cranberry Health Mix sold at Winners, HomeSense and Marshalls in Canada.

As if that weren’t enough; a variety of Amy’s Kitchen natural and organic frozen food products are being recalled from Canadian and US retailers for possible listeria contamination. Listeria symptoms include fever, headache and nausea – appearing up to 70 days after infection. While seldom fatal, listeria can cause miscarriages and stillbirth in pregnant women. Unlike most other bacteria, listeria can grow and spread to other foods in your refrigerator. Recalled items can be returned to the stores where they were purchased for a refund.

Neptune Locks Down Patents

By
IHR Magazine
-
0
Nestle under pressure as Maggi withdrawn from shelves

Neptune Technologies & Bioressources Inc. and Acasti Pharma Inc. announced that on March 23, 2015 the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO) issued a favourable decision, confirming the validity of certain claims in Neptune’s ‘351 patent
(U.S. Patent: 8,278,351) and impelling royalty payments to Neptune.

“This is a significant milestone that triggers the payment of ongoing royalties to Neptune by Aker and Enzymotec, based on their sales of licensed krill oil products in the US,” highlighted Jim Hamilton, President and CEO of Neptune. “The decision clearly supports the validity and enforceability of Neptune’s ‘351 composition of matter patent. Now that the positive decision has been rendered, we can turn our attention to building the industry and growing the krill oil market.”

“Our intellectual property (IP) is a fundamental and valuable asset,” highlighted Benoit Huart, Director Legal Affairs at Neptune. “The positive decision preserves strong IP protection for both our nutraceutical and pharmaceutical businesses and substantiates our IP procurement and enforcement strategy. Aker and Enzymotec may appeal the decision. Regardless, the strength of our patent estate has once again been recognized. We will continue to enforce and build upon it to ensure we have long lasting and comprehensive protection, while preventing others from importing into and selling infringing products wherever we have valid patents.”

On December 17, 2013, Neptune announced that it had successfully concluded a settlement and license agreement with Aker and on April 27, 2014, they completed one with Enzymotec. Neptune granted a world-wide, non-exclusive, royalty-bearing license to both parties to market and sell nutraceutical products in the licensed countries. Pursuant to the terms of these settlements, royalty levels in the US depended on the outcome of an inter parties review at the PTAB of certain claims from Neptune’s ‘351 patent. In light of the PTAB’s decision, Aker and Enzymotec will be obligated to make royalty payments to Neptune based on their sales of licensed krill oil products in the US. Under the terms of the settlement agreement with Enzymotec, their royalty obligations in Australia were similarly dependent on the outcome of a potential request with the Australian Patent Office for a review of certain claims. A patent reexamination recently commenced.

On March 24th, Neptune announced that the Chinese Patent Office has granted Acasti a composition and use patent – valid until 2030 – relating to concentrated therapeutic phospholipid omega-3 compositions and covering methods for treating or preventing diseases associated with cardiovascular diseases, metabolic syndrome, inflammation, neurodevelopmental diseases, and neurodegenerative diseases. “To date, Acasti has received patents in the United States, Australia, Panama and South Africa for its phospholipid composition,” highlighted Benoit Huart, Director Legal Affairs at Acasti. “As well, similar patent applications are pending in more than 40 jurisdictions worldwide and are actively being pursued. This is yet another example of our commitment to build and extend our patent estate.”

“Today’s announcement further enhances the value of our intellectual property, by protecting a vast market and providing potential expansion opportunities for Acasti’s products going forward,” said Pierre Lemieux, PhD, Acasti’s Chief Operating Officer. “There is a large unmet need for high-quality, well-studied and differentiated krill products in China. It is the third largest pharmaceutical market in the world, with an average compound annual sales growth rate of approximately 20% over the past ten years.”

Naturally Splendid Builds Impressive HempOmega Team for Global Push

By
IHR Magazine
-
0
Naturally Splendid Builds Impressive HempOmega Team for Global Push

Naturally Splendid Enterprises made not one but two major appointments to its Corporate Advisory Board to assist the Company with development and marketing strategies for penetrating the $35B global omega market.

The first of these is Former Maple Leaf Foods President, Mr. Ted McKechnie – whose primary focus will be to assist management in the marketing and sales of the Company’s plant based line of omega products licensed under the recent agreement with Full Spectrum Laboratories (FSL). Mr. McKechnie will utilize his extensive network and relationships in the food and beverage industry to generate sales opportunities as they specifically relate to the omega industry.

Additionally, Mr. McKechnie will lend his expertise in the area of wholesale and retail product development, marketing and distribution.
Mr. McKechnie is a senior executive with extensive Board and Senior Management Experience in the consumer goods and service industries. Ted has a proven track record for achieving corporate financial and growth objectives. In addition to his role as President of Maple Leaf Foods, he has held senior positions with Kraft, General Foods, PepsiCo, Frito Lay, Canada’s Technology For Food, The Davies Group of Companies, Ethnic Food Group International, Inc., Humpty Dumpty Foods and Menu At Home.Com. Mr. McKechnie was presented with the Philip Morris Chairman’s Award for “recognition of extraordinary contributions having a significant and lasting impact on the Corporation”.

Naturally Splendid CEO Craig Goodwin states, “Ted brings a world class sales and marketing background to Naturally Splendid. Initially, Ted will provide his expertise in developing our full line of omega products. We look forward to working closely with Ted, and networking with his key industry relationships throughout the food and beverage industry, opening new doors for HempOmega(TM).”

The second appointment to the Corporate Advisory Board is Clearly Canadian beverage founder, Mr. Douglas Mason. Mason’s primary focus will be to assist management with marketing and sales strategies for the Company’s full range of products licensed under the recent agreement with Full Spectrum Laboratories.

Mr. Mason serves as a senior officer and director of a number of public companies. He also has extensive experience in financing and acquisitions in capital markets, raising over $200 million over the past 25 years. He is currently Chairman of the Board and CEO of Waterfront Capital Corporation.

From 1998 through 2005, Mr. Mason served as President, Chief Financial Officer and Director of Clearly Canadian Beverage Corporation, a producer of premium beverage products. During his 20 years in the beverage industry, Douglas built a reputation for innovation and has been credited as being one of the pioneers of the New Age Beverage category.

CEO Craig Goodwin says, “Initially, Douglas will provide his expertise in developing strategies to develop functional beverages incorporating products derived from the recently acquired technology license from Full Spectrum Labs. Beverages are the largest US functional product sector. Globally, the functional beverage market is valued at $68 billion. Our plans, with an experienced team now in place, is to penetrate these markets.”

When is an Apple not an Apple?

By
IHR Magazine
-
0
When is an Apple not an Apple?

A company called Okanagan Specialty Fruits (recently acquired by US Bio-technology firm, Intrexon) has just received Canadian and US approval for its genetically modified (GM) “non-browning” apple – it does not brown when you slice it, for 15 days or more.

The company says the GM apples “have more eye appeal: no yucky browning” – but, according to the Canadian Biotechnology Action Network, (CBAN), sixty-nine per cent of Canadians don’t want it approved. Many groups representing fruit growers in Canada are also opposed. Consumer rejection and possible contamination from GM apples threatens the future of our apples, and the farmers who grow them. The apple will hit the market with two different varieties : Arctic granny and Arctic golden.

Lots of people who don’t object to the apple itself, still believe strongly that the product should be labeled GM so consumers can make an informed choice.
Fred Steele, president of the BC Fruit Growers’ Association told the Penticton Western News, “I’m not arguing the science. But if (Health Canada) decided there’s no problem with it, then there should be no problem labelling it,” he said. “Let’s let the people decide. If it’s fine — fine. If it’s not, (consumers) will let them know.”

While scientific studies have not been able to identify any health risks, many pundits have said things like “how could a food that never goes bad possibly be good for you?”

22 pharmacies across BC selected for first-ever genomics project

By
IHR Magazine
-
0
22 pharmacies across BC selected for first-ever genomics project

Twenty-two pharmacies in rural and urban locations across British Columbia have been selected to participate in a research project that aims to help bring personalized medicine to patients through community pharmacists.

The “Genomics for Precision Drug Therapy in the Community Pharmacy” project is the first of its kind in North America. It is funded by the BC Pharmacy Association (BCPhA) and Genome BC, with research done by a team at the University of British Columbia’s Faculty of Pharmaceutical Sciences.

The research project focuses on using community pharmacists to collect saliva samples to test how an individual’s DNA can impact medication selection and dosage. The project will develop standard operating procedures for the collection of patient saliva samples by community pharmacists as well as procedures for the processing and sequencing of the DNA in these samples by UBC researchers.

Across the province, the 22 pharmacies will recruit 200 volunteer patients, who are currently taking the anticoagulation drug warfarin, to be part of the study. Researchers will do a retrospective analysis of DNA information to learn how genetics would have altered the drug dosage patients were prescribed.

Pharmacy locations include Burnaby, Courtenay, Cranbrook, Enderby, Fort St John, Hope, Houston, Kamloops, Kelowna, Penticton, Port Coquitlam, Port McNeill, Prince George, Surrey, Vancouver, Victoria and Williams Lake.

“Pharmacists, who are experts in medication, are the health-care practitioners best positioned to collect and use patient genetic information to help make medication selection and dosing decisions,” said Geraldine Vance, CEO of the BC Pharmacy Association.

“Over time, the aim is to use DNA to make decisions about the most commonly-prescribed medications, making personalized medicine accessible for all patients in the province.”

There are more than 1,200 community pharmacies across the province, meaning any British Columbian could ultimately have access to this testing regardless of where they live.

“With the modern genome technology used in this project, the idea of personalized medicine can become a reality,” said UBC lead researcher Dr. Corey Nislow.

“We know there are more than 150 medications that are impacted by an individual’s DNA. This project is about using that genetic information to make decisions about which medications are right for a patient – the right drug, in the right dosage at the right time.”

Petitioning Processed Food

By
IHR Magazine
-
0
Petitioning Processed Food

There’s no denying that Kraft Dinner is a tasty product. It has been declared Canada’s official favourite food by any number of pundits and authorities.

But if the logo of The World Health Organization or the Dietitians of Canada suddenly turned up on the box, with an endorsement suggesting that Kraft Dinner is a healthy dietary choice for children, that would almost certainly give rise to a major controversy.

A very similar scenario has been playing out in the US, with “Kids Eat Right – ” a nutrition education campaign created by the Academy of Nutrition and Dietetics, the world’s largest trade group for nutrition professionals. It began with a product label on Kraft Singles, declaring them to be a proud supporter of the Kids Eat Right campaign.

While it’s true that the Kids Eat Right campaign isn’t technically doing the endorsing, the implied relationship is one of mutual support, and many shoppers would not make the distinction. The fact is, the nutritionists appear to be endorsing Kraft Singles. And that doesn’t sit well with all parties concerned. In fact, many members of the Academy of Nutrition and Dietetics were appalled enough to launch a campaign on the social protest site, Change.org asking the group’s leaders to #RepealtheSeal.

While “selling” their endorsements is hardly a rare or novel practice for experts in any field, there has been some scuttlebutt brewing on The Associated Press and other places – pointing out how bloggers are routinely paid to mention certain products on their sites and doctors and nutrition experts often go onto manufacturer’s payrolls to endorse products at public events and in the media.

A Licence to Protest

By
IHR Magazine
-
0
A Licence to Protest

On the March 13 episode of CBC’s Marketplace, called “A Licence to Deceive,” the show’s staff created an imaginary product for the treatment of fever, pain and inflammation in children. They called it Nighton – an anagram for “nothing.” And they got the homeopathic recipe for it from a very old homeopathic encyclopedia – photocopying the three pages of product claims and ingredients directly out of the book. Then they created some fake but effective packaging and submitted it all in a licencing application to Health Canada.

To the Canadian health regulator’s embarrassment, the application was approved and the bogus product got marched out on national television. Dr. Matthew Stanbrook, deputy editor of the Canadian Medical Association Journal provided the observation that the Nighton approval “really makes a joke of the regulatory process.”

In the next segment of the program, a mosquito repellent called Mozi-Q was tested in the lab and proved to be totally ineffective. That product had been funded during a recent episode of Dragon’s Den – when the dragons were convinced of the products efficacy simply by the fact that it had received Health Canada approval. After it failed the test, all funding was withdrawn.

Likewise, a panel of parents who told Marketplace that they would have purchased Nighton – largely based on the Health Canada approval – expressed their disillusionment and loss of faith in the approval system.

Manufacturers and retailers of naturopathic products should all be very concerned about Health Canada’s loss of credibility during this episode. No matter how good the product you have spent years and millions of dollars developing, no matter how unimpeachable the lines of medicines and supplements you sell in your store, this kind of publicity undermines consumer faith in all products submitted for Health Canada approval.

Maybe it’s time for everyone in the industry to raise their voices as one and demand tougher licencing regulations.

McKesson Acquires Remedy’sRx: Appoints Richard Brennan to Guide Their Growth into Retail

By
IHR Magazine
-
0
McKesson Acquires Remedy'sRx: Appoints Richard Brennan to Guide Their Growth into Retail

McKesson Canada president, Alain Champagne, says they’re often described as “the largest company you’ve never heard of.” Whereas not long ago (2011), they were merely Canada’s largest drug distributor, McKesson is now invested in retail, supporting their own banner programs with close to 1,500 pharmacies across the country.
On February 26th, McKesson completed the acquisition of Remedy’sRx – the fastest-growing independent pharmacy network in Canada, with 272 locations across the country. Spokesperson Andrew Ross at McKesson told us that there are no current plans for changes at Remedy’sRx – the 35 employees at Remedies head office will be integrated into the larger company, as McKesson banks on the expertise of employees both old and new. Their goal, said Ross is simply to “make Remedy’sRx into an even stronger brand.
Entering this new phase of expansion, McKesson Canada has appointed Richard Brennan to the position of Senior Vice President, Retail Banner Management Services. In this role, Brennan will be responsible for leading McKesson Canada’s growing pharmacy banner business that include Guardian, I.D.A., The Medicine Shoppe Canada, Proxim and now, Remedy’sRx. He will report to McKesson Canada’s President, Alain Champagne, and will become a key member of the company’s Canadian Executive Team.
Mr. Brennan joined McKesson Canada fourteen years ago and has played roles of increasing responsibility. Prior to joining McKesson Canada, Brennan spent eighteen years at Shoppers Drug Mart, where he played a number of leadership roles with a clear focus on driving merchandising and operational excellence.
“I am excited to welcome Richard to the Executive Team,” said Champagne.

Have Scripps Research, Mayo Clinic Scientists Found a Cure for Aging??

By
IHR Magazine
-
0

“Senolytics” are a new class of drugs that In animal models, dramatically slows the aging process—alleviating symptoms of frailty, improving cardiac function and extending a healthy lifespan.

The research, being done by teams from The Scripps Research Institute (TSRI), Mayo Clinic and other institutions appeared on March 9th in the journal Aging Cell.

Senescent cells are cells that have stopped dividing. They accumulate with age and accelerate the aging process.

Killing off these cells, increases the healthspan in mice, so scientists are hopeful about finding treatments that can have the same effect in humans.
Drug testing show that the cancer drug dasatinib (sold under the trade name Sprycel®) eliminated senescent human fat cell progenitors. Quercetin, a natural compound sold as a supplement that acts as an antihistamine and anti-inflammatory, was more effective against senescent human endothelial cells (a single layer of smooth, thin cells that lines the heart, blood vessels and lymphatics) and mouse bone marrow stem cells. A combination of the two was most effective overall.

In old mice, cardiovascular function was improved within five days of a single dose of the drugs. A single dose of a combination of the drugs led to improved exercise capacity in animals weakened by radiation therapy used for cancer. The effect lasted for at least seven months following treatment with the drugs. Periodic drug administration of mice with accelerated aging extended the healthspan in the animals, delaying age-related symptoms, spine degeneration and osteoporosis.

“We view this study as a big, first step toward developing treatments that can be given safely to patients to extend healthspan or to treat age-related diseases and disorders,” said TSRI Professor Paul Robbins, PhD, who with Associate Professor Laura Niedernhofer, MD, PhD, led the research efforts for the paper at Scripps Florida. “When senolytic agents, like the combination we identified, are used clinically, the results could be transformative.”

The authors caution that more testing is needed before use in humans. They also note both drugs in the study have possible side effects, at least with long-term treatment.

The co-first authors of the study, “Achilles’ Heel of Senescent Cells: From Transcriptome to Senolytic Drugs,” are Yi Zhu and Tamara Tchkonia of the Mayo Clinic.

1...272273274...389Page 273 of 389

EDITOR PICKS

POPULAR POSTS

POPULAR CATEGORY

© 2026 IHR Magazine | Canada's Natural Health Industry Authority | Le guide de l’industrie canadienne de la santé naturelle